<SEC-DOCUMENT>0001641172-25-006782.txt : 20250430
<SEC-HEADER>0001641172-25-006782.hdr.sgml : 20250430
<ACCEPTANCE-DATETIME>20250430070008
ACCESSION NUMBER:		0001641172-25-006782
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250430
FILED AS OF DATE:		20250430
DATE AS OF CHANGE:		20250430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		25890846

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>April
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2025, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing today, its plans to accelerate the clinical
development of urcosimod to treat NCP through the analysis of its data following the early closure of its Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 30, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">News Announcement, dated April 30, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Urcosimod
    phase 2 trial treating Neuropathic Corneal Pain (&ldquo;NCP&rdquo;) patients was initiated in October 2024 and designed as a double-masked,
    randomized, 12-week placebo-controlled trial.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
    Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
    Pharma plans for a meeting with FDA following evaluation of clinical data. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, April 30, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing
urcosimod (formerly called OK-101) to treat NCP<FONT STYLE="background-color: white">, an ocular condition associated with chronic and
often severe pain but without an FDA-approved therapy</FONT>, announces plans to accelerate the clinical development of urcosimod to
treat NCP through the analysis of its data following the early closure of its Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 trial of urcosimod to treat NCP was being conducted at a single trial site at Tufts Medical Center in Boston, MA. The decision
to close the trial now, with 17 patients having presently completed the study, is due to OKYO&rsquo;s strong desire to access the currently
masked data and use it to plan its expanded development program. The patients participating in the trial have all been diagnosed with
long term chronic neuropathic corneal pain and had previously been treated with multiple therapies with very limited or no response.
Significant interest has been seen in the trial from long-term sufferers of NCP, and OKYO believes it should expand the development program
and move forward with a multicenter trial. A considerable number of potential patients have expressed an interest in participating in
a future registrational trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of patients who have now completed the trial have requested continued compassionate use of urcosimod which the Company is seeking
to arrange with Tufts Medical Center, subject to the necessary FDA consents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;By
ending this trial now, we believe we can save time in advancing the program to a meeting with FDA to discuss further development of urcosimod,&rdquo;
commented Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma. &ldquo;We anticipate that the analysis of the data from these
patients with the closing of this trial should take no longer than 6 weeks. Urcosimod has already demonstrated favorable safety and
placebo-like tolerability in our previous 240 patient Phase 2 trial. The decision to close the trial now significantly cuts the time
to our requesting an end-of-phase 2 meeting with FDA to explore accelerated plans for the drug&rsquo;s further clinical development.
I want to also thank our patients and study site team for their participation and commitment to this important trial of urcosimod to
treat NCP.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NCP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal
pain is unknown but is thought to result from nerve damage to the cornea combined with inflammation. Neuropathic corneal pain, which
can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated
by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Urcosimod Phase 2 Trial in NCP Patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 study was designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients were
planned to enroll for the study, with NCP disease confirmed <I>via</I> confocal microscopy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Urcosimod (Formerly called OK-101)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Urcosimod
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed
using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has
been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain,
respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially
enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints
in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and was also being evaluated
in <FONT STYLE="background-color: white">a randomized, placebo-controlled, double-masked Phase 2 trial to treat neuropathic corneal pain
patients.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery
and development of novel molecules to treat neuropathic corneal pain and dry eye disease. In addition to the completed Phase 2 trial
of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
                                            (0)20 7495 2379</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 2P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBJ%Y>
M6]I;W5S<W45I;VD3W%S<W$BPV]M;P(99YYY962.&"*)6DEFD811QJ[NP5691
M:ORZOHEW?ET_X GTT;NTDHKFDW)J*2BM9-MI*,4Y2;22;:3M2'KUY4=/J<_3
M'7/;\>/#/CO^T=\#OV9? MU\1_CS\2_#/PQ\&VK^5'J7B*ZD2\U6\V[ET[PY
MH5C;WNO^)]6=-S1Z5X<TO4]3DC221+4Q1O(/P^_;U_X+X> /A9JFH?!+]B71
M;/\ :-^.%U<W6@/XRLK+4M<^&7A75P/(\KP[9Z&7U/XO>(;>9F,-CX;N;7PL
M)D0MXAU5UFTI_P"6C]MWP_\ MKW/B_PK\4_VZM0\7I\3OBIIVIZYX5\,_$G7
M;!?'6E^#+>[%J-0M_AE8S[OA9X(N]36ZTW0=*ET3PO'JE]INKSV>EW$5K->/
MR5\:J2?LESN+M)I>Y%[:NUWOHHWNVM=[?TSX9?1JSWBS%99BN-<PAP3E69*I
M5R[*\7+#QXQS^C0IO$5)9;D.*J*M@,#3P\?;5<VS7 *-&A45:.$:=)5/WA_:
MR_X.4]1GN=2\+_L7_"2SCL4>>UC^+'QQL[J9[H!T5+_PU\-=!U:PDM@RB:2S
MN_%OB)Y&9X3?^$XA'+:3?@M\9O\ @HS^W1\?+V\N_B7^U'\7;RSO;F6Y/AOP
MOXGNOA[X1MO,,ACM[;PMX!_X1O1_*MHY/(@:ZM;NX\I%\R=YBTC>K?L._P#!
M*?\ :M_;M$7B/P%H%AX"^#T=Z]G>_&;XBF[T[PK/-!O-W;^$=+@C?7/'-W;O
M$MM,VBVZ:/:W4PMM2UVQGRJ?T7_"7_@VD_98\-V,,OQE^,?QC^*^L"SA%RGA
MB30/AAX;%V#NN)(+**Q\5:\\+$>3"K>(E(0&1P9&_=\EL=BTF^:$)7Y4ZOLH
MVTV26M]-?1/8_I?$9O\ 1D\"J\LIIX3*\9Q'A(JGC(PRJIQKQ)1J-1<WCLQQ
MKK9?EN(C+64:<L!.BY14,)A(.-,_BUO-3U34;M]1U'4]0U'4)9#--J.H7MU?
M7\LC,9#))>74SSO+NPPED9FRJC SE?H7X3_ME_M:_ J^M]0^$?[1WQC\#O:I
M'%%I^G^.]=U'P\T$&&BMKOPKKUWJWA>_M8Y%4I;7VC7%N%# PN6##^TR?_@W
MH_X)MS6K6T?A3XM6LI3:+VV^+FNFZ4G(W 3VT]J2"0?GM67@94@$5\M?%S_@
MV6_9ZUV&^N?@C\?_ (L?#K4&@SI^G>/-+\-?$O0$NDB?Y)I+"'P-KD-K<R^5
MO<ZA>7%JHD>*&XW",PL!BJ?O1:37\K:;\KM+^K=#HC]*'P+SY++,YP>9TL#4
MM2MGO!U''993IW5X5J,*N;/V33;]I' 5IT]UR).2^:?V*_\ @X^\4V>JZ1X(
M_;G\&Z?K.@W,UK8I\<?A7H4]CKFD>:3$=2\=_#N"ZN+'6[5"ZS7VH> (M(O+
M:W1WM?!>J2HQF_K#^%WQ0^'OQF\$^&_B7\*?%^@^// 'BW35U3P[XJ\-W\6H
MZ7J=H^Q7V2IB2VN[:?S+34-.O([?4=.O8+BQU"UMKRWF@3^ _P#:G_X(B?MW
M?LR6^J>(K3P':_'GX>Z9%/<W'B[X+&\\0ZE:Z=;YGEN=7^'MQ##XVM8X+='E
MNY-,TSQ!96ZB222_C5?.C\>_X)Y?\%(/C;_P3O\ B:VH>&Y+_P 5?"+7-4A@
M^+/P2UB\NK/3=7BMI1:WNM>'DNF>'PC\1-+@B98=96T$5X+=-'\16^HZ?%;M
M:[4\96HM4\5"5K\L9R6JZ)Z*S2[W?74^"X[\ /#SQ*R;%<7^!F9Y,\SHJI5Q
M&193F%&KDN8N-&>)CAJ>$J3>)X;S>O&\*-/%0PV75ZG+1K4\#7JTJ\?])6BO
M#?V>_P!H/X6?M0?"3P=\:O@UXJA\5>!/&5I]IL;M5^SZEIM["XBU/P[XATUQ
M]HT?Q%H=V&L-7TJZ DMYT+Q2W%I-;7<_N5>GT3334E=-;-'\&8G#8G!8K$X+
M&X:O@\9@Z]7#8O"XFE.AB,/B*$Y4ZU&M2J1A.G5I5(3IU(3A&490:::<6RJT
MTD<22R32QPQ1K))++)((HXXHXU>2221BJQHB*79R0$4;B0!D6:^,/^"B?BK4
MO W[!7[:OC#1KB>SUCP]^RM\>M3TN^MII;>XLK^#X8>(UM;RWN()(YH+BUF,
M=Q;RPNDL4T2R1NK*"-L-0>*Q6$PJ:C+$XK#8>,FKJ,J^(H4(S?7]VZW/IK>-
MNIPXJNL-AL1B'%R5"A7KN*WE["A6KJ/I-T>25_LR?70_A[_X*7_\',_[5GQ=
M^*GC?X=_L*^,X/@)^SQX<UR]T+PW\2M!T/2[[XO?%FVTFXFL+CQ?<:YXGLM6
ML_!/A;7YH5OO"VA^'-%TSQ/;Z7Y%UKOB%[O49=(TK\-O$7_!2[_@H9XFO3>>
M(OVZOVM;ZZ<_*S_M"_%&S1.Y$5MIWB>TLH8R&!$4,$*J"=B 9 ^-=$T]]4N]
M)T>%EBDU2?3M,@E905AFOKB"QBE(VG'EF15+ X\M5XV1*#_K]_LW?\$X_P!B
MO]F;X5>#?A7\.OV:/@O!8^&O#FD:5J7B+6?AOX.\0>,_&&J6-I&E]XD\:>+M
M5T2XUOQ+K^JWK75Y=WVI7<NR2<P645G8I;VD'])Y]C.%?#?!Y7A:7#F&S"KB
MH5*=)NC@57J4\)##JIBL97Q5#$RG5J5*[?[OE<=4H\L8W_$\JPN?<:XK,:L\
MZKX2CAYQFZ:JXIT8NO*M[.G0HX>M0C&%*%)1M.4KV3LW)L_RK_\ AX1^W9_T
M>U^UC_XD?\7/_FRIR?\ !0C]O!71X_VW/VLE=""K?\-'?%TX(.1T\8E020.7
MPAQ@\D5_KF?\,T?LX_\ 1O\ \$O_  U/@3_Y0U'+^S%^S7/&\,_[/7P.FB=6
M1XI?A-X"DC='4HZNCZ 5971BK*00RDJ002*^8_XBSD7_ $16&_\  LK_ /G4
M>W_Q#O-5K'B6HGWY<P_3,#_+/^#/_!;;_@JA\#]<TS6_#7[:OQD\6P:?-%*W
MAKXQ:Y'\9?"FJVZ(Z-I^I:?\05US4(K"9'(+Z)J>C:@FQ9K74(F177^RKX,_
M\%>Y_P#@H[_P1<_X*(?%O2XG^#/[4O[/?[+'QOL_B?IWPZUC7=)M_#?BN\^#
M7C36O /Q2^%^M/>R^(]!T7Q-<:%J]QH5O/KEYX@\*Z]X9U;3GU?4!86.NZI^
M#_\ P=*?L0_ 7]E;]H3]GGXI?L_?#7PE\(M)^/\ X%^(%OXY\&> M'L?#7@Z
M;QI\-]=T"5?%FF>%M-@@TC1-2U_1?&UE8:VFC6]CIU])H%CJ3:>NJW.IW]_\
MA?\ !%_Q'>6GP1_X+9>$HY9AI_B+_@D?^T/XANX%FD$#WO@[3;BRTV66 ,(G
MEA@\;:LD,K*7B6XG1&"SR*?H<TRSASB?AK+.*\!E6'P&)IXS*\53]G1P=&3I
MT\]P.%Q6"Q<,+AJ>&Q//S3DJDJ'-&U-ZJ52+\S*\=G.29_BL@QV/K8V@Z.+H
MSC4JU*L&WEN)Q%&M0==2K44DE%P5649>^FG:+7Y\^%?V^?VZ+CQ5X6MY_P!M
M3]K*:"7Q)X?MYH9?VA_BU+%)')K5DC1S1MXMVR1/'\DD;95U+(P(+"O]A4_>
M/0 $$Y';CIC/4G\>]?XG'@_CQAX2;. /%/AO=TQSJ]HV21C +\9X&2!P< _[
M"_[9G[:O[//[!GP6USXZ_M'^.;?PCX3T^5M/T32+1%U+QEX_\2R6\L^G^#/
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M/4O#%UXY^,IF#6M_I&G^)-%U.+0/AM'#-9:K)81:SXJNK_2)(O#U_P#S@?\
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MNEH[16B26G^=3_P3(Y_X*-_L)9[_ +6_P"'TQ\2/#8_KGZCTXK_8'7F3_=)
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MT^-2UUJ-[9VT:GS"1^ __!NI#XV^+FJ?M\_MI>/8+Y=5_:&^-^DVT-S*;?\
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M3=[)7-:7 ]6M1>)P_%\JU"*FY8BE5Q$Z,%37/4<IPS22BH13;N]'9OW=3_)
M\(>"_C7^TE\1#I?@GPS\4?CY\4O&.HQM/!X>TOQ1\2_&_B+4[HI;QW-_<6\>
MKZM>3DA(I;_4;AHX8(BTLX@MR!_;5^QW_P $I_'O_!.G_@B;_P %4?B;^T/8
M:=H7[17[2/[&'QJN?$'@V*]L-4D^%'PY\'?!KXCS>%O!FIZQ9>=8OXMU#4_$
M^MZYXVAT>_OM'@F3PYI*7EU<Z'-=/_3E^Q3^TQ^R_P#M;? RR^,G['][:7GP
M:U/Q+XCT"TO;'X<ZY\+89?$/AJXBT[75_P"$6\1^'/"VJ#R91#$NHMI8M[M4
M'D3R)$-GU-J&CZ7KFF:CHFMZ;8ZOHVKV=WINJZ1J]I;:GI>K:??PO;WUAJ&G
MW4<MI?65[;R/!=6MU%);SPO)')&RLP/S'%'B7F68SH96\G_LG"Y?F&$J8W!S
MJ3J8ZK+ 8O"XI8&M*.&PE"A14Z,9.,*7/%QAS2M%I^YP_P %8'+ZD\P_M"69
M8G$86LL)BN2$</%8BC6I.O",*]6K4J.$YIU)^ZK.S39_BC^#KRR'C#PE_I=M
MA?%/APY\^+!0:[9,7SO^ZH89;H"P'4@5_MFR!7RK#(+H>02 5YSQW4@%3V8
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M)%*5:A2JR;IQFZ&)H5G!N24'5C?DY=>_^3H?^"AG[<V#C]N#]JKGCC]HWXN
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M4=O926&IV5Q#<PS0Q*)$F4L!("$]"B7:I'/WB3G&<D#/   'M@8Z=*^(XO\
M$7,.):$<MIX&.3X*C6C.K0C7E6Q->MAW*-.-22H82.&AA9^UBJ%&DM?=JO\
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M)S^T1I.DIJUB)KFU6'46TR^OK(2B3>UM<3Q<)(X;^O5O^"//_!'95)7]B_\
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#C__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
